Список литературы

1. Bouroncle B.A.; Wiseman B.K.; Doan C.A. Leukemic reticuloendotheliosis. Blood. 1958; 13: 609 - 630.

2. Went P.T.; Zimpfer A.; Pehrs A. et al. High specificity of combined TRAP and DBA.44 expression for hairy cell leukaemia. American Journal of Surgical Pathology. 2005; 29: 474 - 478.

3. Falini B.; Tiacci E.; Liso A. et al. Simple diagnostic assay for hairy cell leukaemia by immunocytochemical detection of annexin A1 (ANXA1). Lancet. 2004; 363: 1869 - 1870.

4. Foucar K.; Falini B.; Catovsky D.; Stein H. Hairy cell leukaemia. In: WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues. (ed. by Swerdlow SH, Campo E, Harris NL, et al.), pp. 188 - 190. IARC Press, Lyon. 2008.

5. Miranda R.N.; Briggs R.C.; Kinney M.C. et al. Immunohistochemical detection of cyclin D1 using optimized conditions is highly specific for mantle cell lymphoma and hairy cell leukaemia. Modern Pathology. 2000; 13: 1308 - 1314.

6. Chen Y.H.; Tallman M.S.; Goolsby C.; Peterson L. Immunophenotypic variations in hairy cell leukemia. American Journal of Clinical Pathology. 2006; 125: 251 - 259.

7. Del Giudice I.; Matutes E.; Morilla R. et al. The diagnostic value of CD123 in B-cell disorders with hairy or villous lymphocytes. Haematologica. 2004; 89: 303 - 308.

8. Tiacci E.; Trifonov V.; Schiavoni G. et al. BRAF mutations in hairy cell leukemia. New England Journal of Medicine. 2011; 364: 2305 - 2315.

9. Else M.; Dearden C.E.; Matutes E. et al. (2009) Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis. British Journal of Haematology. 2009; 145: 733 - 740.

10. Mercieca J.; Puga M.; Matutes E. et al. Incidence and significance of abdominal lymphadenopathy in hairy cell leukaemia. Leukaemia and Lymphoma. 1994; 14 (Suppl. 1): 79 - 83.

11. Mercieca J.; Matutes E.; Emmett E. et al. 2-chlordeoxyadenosine in the treatment of hairy cell leukaemia: differences in response in patients with and without abdominal lymphadenopathy. British Journal of Haematology. 1996; 93: 409 - 411.

12. Аль-Ради Л.С.; Пивник А.В. Особенности течения и современная тактика терапии волосатоклеточного лейкоза. Клиническая онкогематология. Фундаментальные исследования и клиническая практика. 2009; 2(2): 111 - 120.

13. Maloisel F.; Benboubker L.; Gardembas M. et al. Long-term outcome with pentostatin treatment in hairy cell leukemia in patients. A French retrospective study of 238 patients. Leukemia. 2003; 17: 45 - 51.

14. Dearden C.E.; Else M.; Catovsky D. Long-term results for pentostatin and cladribine treatment of hairy cell leukemia. Leukaemia and Lymphoma. 2011; 52 (Suppl. 2): 21 - 24.

15. Zinzani P.L.; Tani M.; Marchi E. et al. Long-term follow-up of the front-line treatment of hairy cell leukemia with 2-cholordeoxyadenosine. Haematologica. 2004; 89: 309 - 313.

16. Zinzani P.L.; Pellegrini C.; Stefoni V. et al. (2010) Hairy cell leukaemia: evaluation of the longterm outcome in 121 patients. Cancer. 2010; 116: 4788 - 4792.

17. Cervetti G.; Galimberti S.; Andreazzoli F. et al. Rituximab as treatment for minimal residual disease in hairy cell leukaemia. European Journal of Haematology. 2004; 73: 412 - 417.

18. Juliusson G.; Heldal D.; Hippe E. et al. Subcutaneous injections of 2-chlorodeoxyadenosine for symptomatic hairy cell leukaemia. Journal of Clinical Oncology. 1995; 13: 989 - 995.

19. Robak T.; Jamroziak K.; Gora-Tybor J. et al. Cladribine in a weekly versusdaily schedule for untreated hairy cell leukemia: final report from the Polish Adult Leukaemia Group (PALG) of a prospective, randomised, multicenter trial. Blood. 2007; 109: 3672 - 3675.

20. Zenhausern R.; Leupin N.; Hsu Schmitz S.F. et al. A randomized study of daily versus weekly administration of 2 chlorodeoxyadenosine in patients with hairy cell leukemia. Blood. 2007; 110: 1352a.

21. Chadha P.; Rademaker A.W.; Mendiratta P. et al. (2005) Treatment of hairy cell leukaemia with 2-chlorodeoxyadenosine (2-CdA): long-term follow-up of the Northwestern University experience. Blood. 2005; 106: 241 - 246.

22. Liliemark J.; Albertioni F.; Hassan M.; Juliusson G. (1998) On the bioavailablity of oral and subcutaneous 2-chloro-2'-deoxyadenosine in humans: alternative routes of administration. Journal of Clinical Oncology. 1998; 10: 1514 - 1518.

23. I.; Debski R.; Samsel M. Hairy cell leukemia in pregnancy. Ginekol Pol. 2005; 76(11): 898 - 901.

24. Pileri S.; Sabattini E.; Poggi S. et al. Bone marrow biopsy in hairy cell leukaemia (HCL) patients, histological and immunohistological analysis of 46 cases treated with different therapies. Leukemia and Lymphoma. 1994; 14 (Suppl. 1): 67 - 71.

25. Konwalinka G.; Schirmer M.; Hilbe W. et al. Minimal residual disease in hairy cell leukaemia after treatment with 2 chlorodeoxyadenosine. Blood Cells Molecules and Diseases. 1995; 21: 142 - 151.

26. Cervetti G.; Galimberti S.; Andreazzoli F. et al. Rituximab as treatment for minimal residual disease in hairy cell leukaemia extended follow-up. British Journal of Haematology. 2008; 143: 296 - 298.

27. Else M.; Osuji N.; Forconi F. et al. The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent. refractory hairy cell leukaemia. Cancer. 2007; 110: 2240 - 2247.

28. Ravandi F.; Jorgensen J.L.; O'Brien S.M. et al. Eradication of minimal residual disease in hairy cell leukaemia. Blood. 2006; 107: 4658 - 4662.

29. Sigal D.S.; Sharpe R.; Burian C.; Saven A. Very long-term eradication of minimal residual disease in patients with hairy cell leukaemia after a single course of cladribine. Blood. 2010; 115; 1893 - 1896.

30. Аль-Ради Л.С.; Пивник А.В.; Зингерман Б.В.; Кравченко С.К. Лечение рецидивов волосатоклеточного лейкоза. Терапевтический архив. 2012; 84(7): 4 - 9.

31. Else M.; Dearden C.E.; Matutes E. et al. Rituximab with pentostatin or cladribine; an effective combination treatment for hairy cell leukaemia after disease recurrence. Leukemia and Lymphoma. 2011; 52 (Suppl. 2), 75 - 78.

32. Grever M.R. How I treat hairy cell leukaemia. Blood. 2010; 115: 21 - 28.

33. Thomas D.A.; O'Brien S.; Bueso-Ramos C. et al. (2003) Rituximab in relapsed or refractory hairy cell leukemia. Blood. 2003; 102: 3906 - 3911.

34. Nieva J.; Bethel K.; Saven L. Phase 2 study of rituximab in the treatment of cladribine-failed patients with hairy cell leukaemia. Blood. 2003; 102: 810 - 813.

35. Dearden C.; Catovsky D. (1990) Treatment of hairy cell leukaemia with 2-deoxycoformycin. Leukemia and Lymphoma. 1990; 1: 179 - 185.

36. Catovsky D. Clinical experience with 2-deoxycoformycin. Hematology and Cell Therapy. 1996; 38: S103 - S107.

37. Summers T.; Jaffe E. Hairy cell leukemia diagnostic criteria and differential diagnosis. Leukemia and Lymphoma. 2011; 52 (Suppl. 2), 6 - 10.

38. Robak T. Management of hairy cell leukemia variant. Leukemia and Lymphoma. 2011; 52 (Suppl. 2), 53 - 56.

39. Noel P. Definition of remission, minimal residual disease, and relapse in hairy cell leukemia bone marrow biopsy histology and immunophenotyping. Leukemia and Lymphoma. 2011; 52 (Suppl. 2), 65 - 68.

40. Daver N.; Nazha A.; Kantarjian H.M. et al. Treatment of hairy cell leukemia during pregnancy: are purine analogues and rituximab viable therapeutic options. (http://www.ncbi.nlm.nih.gov/pubmed/22981963) Clin Lymphoma Myeloma Leuk. 2013; 13(1): 86 - 9.

41. Dietrich S.; Glimm H.; Andrulis M. et al. BRAF Inhibition in Refractory Hairy-Cell Leukemia N Engl J Med 2012, 366; 21.

42. Урнова Е.С.; Аль-Ради Л.С.; Кузьмина Л.А.; Карякина А.А.; Ковригина А.М.; Двирнык В.Н.; Якутик И.А.; Судариков А.Б.; Паровичникова Е.Н.; Савченко В.Г. Успешное применение вемурафениба у больного с резистентной формой волосатоклеточного лейкоза. Терапевтический архив, 2013, N 7, с. 76 - 78.

43. Sari E.; Nagy Z.G.; Baghy K. et al. Treatment of refractory hairy cell leukemia with a BRAF-inhibitor: lessons to be learnt. Pathol Oncol Res. 2014 May.

44. Cornet E.; Delmer A.; Feugier P. et al. Recommendations of the SFH (French Society of Haematology) for the diagnosis, treatment and follow-up of hairy cell leukaemia. (http://www.ncbi.nlm.nih.gov/pubmed/24994538) Ann Hematol. 2014; 93(12): 1977 - 83.

45. Robak T (http://www.ncbi.nlm.nih.gov/pubmed/?term=RobakT[Author]&cauthor=true&cauthor_uid=26269205).; Matutes E (http://www.ncbi.nlm.nih.gov/pubmed/?term=MatutesE[Author]&cauthor=true&cauthor_uid=26269205).; Catovsky D (http://www.ncbi.nlm.nih.gov/pubmed/?term=CatovskyD[Author]&cauthor=true&cauthor_uid=26269205). et al. Hairy cell leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. (http://www.ncbi.nlm.nih.gov/pubmed/?term=ESMO hairy cell) 2015; 26 Suppl 5: v100-7.

46. Jones G (http://www.ncbi.nlm.nih.gov/pubmed/?term=JonesG[Author]&cauthor=true&cauthor_uid=22111844).; Parry-Jones N (http://www.ncbi.nlm.nih.gov/pubmed/?term=Parry-JonesN[Author]&cauthor=true&cauthor_uid=22111844).; Wilkins B (http://www.ncbi.nlm.nih.gov/pubmed/?term=WilkinsB[Author]&cauthor=true&cauthor_uid=22111844). et al. Revised guidelines for the diagnosis and management of hairy cell leukaemia and hairy cell leukaemia variant. Br J Haematol. (http://www.ncbi.nlm.nih.gov/pubmed/22111844) 2012; 156(2): 186 - 95.

47. Osman H (http://www.ncbi.nlm.nih.gov/pubmed/?term=OsmanH[Author]&cauthor=true&cauthor_uid=23750990).; Roth T (http://www.ncbi.nlm.nih.gov/pubmed/?term=RothT[Author]&cauthor=true&cauthor_uid=23750990).; Zhou J (http://www.ncbi.nlm.nih.gov/pubmed/?term=ZhouJ[Author]&cauthor=true&cauthor_uid=23750990). Hairy cell lymphoma: a unique presentation of hairy cell leukaemia. Br J Haematol. (http://www.ncbi.nlm.nih.gov/pubmed/23750990) 2013; 162(3): 294.